{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:21:25Z","timestamp":1778073685261,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA218659"],"award-info":[{"award-number":["R01CA218659"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01EB026207"],"award-info":[{"award-number":["R01EB026207"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00270-022-03242-8","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T18:03:00Z","timestamp":1660327380000},"page":"1834-1841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"45","author":[{"given":"Jason","family":"Pe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bongseo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Woo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-3319","authenticated-orcid":false,"given":"Dong-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"issue":"12","key":"3242_CR1","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s12276-020-00527-1","volume":"52","author":"E Kim","year":"2020","unstructured":"Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12):1898\u2013907.","journal-title":"Exp Mol Med"},{"issue":"4","key":"3242_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","volume":"103","author":"A Sergio","year":"2008","unstructured":"Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103(4):914\u201321.","journal-title":"Am J Gastroenterol"},{"issue":"13","key":"3242_CR3","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3748\/wjg.v10.i13.1876","volume":"10","author":"Z Li","year":"2004","unstructured":"Li Z, Hu DY, Chu Q, Wu JH, Gao C, Zhang YQ, Huang YR. Cell apoptosis and regeneration of hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol: WJG. 2004;10(13):1876\u201380.","journal-title":"World J Gastroenterol: WJG"},{"issue":"3","key":"3242_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2217\/fon.13.11","volume":"9","author":"G Han","year":"2013","unstructured":"Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, Feng G, Yang R, Lu L, Chao Y, Wang J. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol. 2013;9(3):403\u201310.","journal-title":"Future Oncol"},{"issue":"8","key":"3242_CR5","first-page":"585","volume":"14","author":"JF Geschwind","year":"2016","unstructured":"Geschwind JF, Chapiro J. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma. Clin Adv Hematol Oncol. 2016;14(8):585\u20137.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"6","key":"3242_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/ijc.29126","volume":"136","author":"Y Chao","year":"2015","unstructured":"Chao Y, Chung Y\u00c4, Han G, Yoon J\u00c4, Yang J, Wang J, Shao G\u00c4, Kim BI, Lee T\u00c4. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136(6):1458\u201367.","journal-title":"Int J Cancer"},{"issue":"10","key":"3242_CR7","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1051-0443(07)61862-4","volume":"13","author":"JF Geschwind","year":"2002","unstructured":"Geschwind JF. Chemoembolization for hepatocellular carcinoma: where does the truth lie? J Vasc Intervent Radiol: JVIR. 2002;13(10):991\u20134.","journal-title":"J Vasc Intervent Radiol: JVIR"},{"issue":"4","key":"3242_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/01.COC.0000020588.20717.BB","volume":"26","author":"JF Geschwind","year":"2003","unstructured":"Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharek MS. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol. 2003;26(4):344\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"3242_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429\u201342.","journal-title":"Hepatology"},{"issue":"10","key":"3242_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/bjs.1800701009","volume":"70","author":"MN Chamberlain","year":"1983","unstructured":"Chamberlain MN, Gray BN, Heggie JC, Chmiel RL, Bennett RC. Hepatic metastases: a physiological approach to treatment. Br J Surg. 1983;70(10):596\u20138.","journal-title":"Br J Surg"},{"issue":"5","key":"3242_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/cncr.11168","volume":"97","author":"Y Komorizono","year":"2003","unstructured":"Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, Kohara K, Shigenobu S, Ishibashi K, Arima T. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003;97(5):1253\u201362.","journal-title":"Cancer"},{"issue":"5","key":"3242_CR12","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164\u201371.","journal-title":"Hepatology"},{"issue":"19","key":"3242_CR13","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.3748\/wjg.v10.i19.2878","volume":"10","author":"X Li","year":"2004","unstructured":"Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10(19):2878\u201382.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3242_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","volume":"8","author":"AX Zhu","year":"2011","unstructured":"Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292\u2013301.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3242_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423\u201336.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"3242_CR16","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1158\/1535-7163.MCT-08-0715","volume":"7","author":"J Ma","year":"2008","unstructured":"Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7(12):3670\u201384.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3242_CR17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/IGC.0b013e31823c6efd","volume":"22","author":"D Teoh","year":"2012","unstructured":"Teoh D, Secord AA. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22(3):348\u201359.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"3242_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1159\/000510299","volume":"9","author":"Y Kawamura","year":"2020","unstructured":"Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Tominaga L, Kajiwara A, Kasuya K, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Lenvatinib-transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma. Liver Cancer. 2020;9(6):756\u201370.","journal-title":"Liver Cancer"},{"issue":"8","key":"3242_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1159\/000515865","volume":"99","author":"Y Ando","year":"2021","unstructured":"Ando Y, Kawaoka T, Amioka K, Naruto K, Ogawa Y, Yoshikawa Y, Kikukawa C, Kosaka Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Fukuhara T, Mori N, Takaki S, Tsuji K, Nonaka M, Hyogo H, Aisaka Y, Masaki K, Honda Y, Moriya T, Naeshiro N, Takahashi S, Imamura M, Chayama K, Aikata H. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolization sequential therapy for patients with intermediate-stage hepatocellular carcinoma. Oncology. 2021;99(8):507\u201317.","journal-title":"Oncology"},{"issue":"10126","key":"3242_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, Baron A, Park J-W, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng A-L. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"1","key":"3242_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","volume":"55","author":"T Yamashita","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. REFLECT: a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113\u201322.","journal-title":"J Gastroenterol"},{"issue":"62","key":"3242_CR22","doi-asserted-by":"publisher","first-page":"8810","DOI":"10.1039\/D0CC03614E","volume":"56","author":"W Zhang","year":"2020","unstructured":"Zhang W, Choi H, Yu B, Kim D-H. Synthesis of iron oxide nanocube patched Janus magnetic nanocarriers for cancer therapeutic applications. Chem Commun. 2020;56(62):8810\u20133.","journal-title":"Chem Commun"},{"issue":"16","key":"3242_CR23","doi-asserted-by":"publisher","first-page":"13819","DOI":"10.1021\/acsami.7b02258","volume":"9","author":"W Park","year":"2017","unstructured":"Park W, Gordon AC, Cho S, Huang X, Harris KR, Larson AC, Kim D-H. Immunomodulatory magnetic microspheres for augmenting tumor-specific infiltration of natural killer (NK) cells. ACS Appl Mater Interfaces. 2017;9(16):13819\u201324.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"3242_CR24","first-page":"e200006","volume":"3","author":"W Park","year":"2021","unstructured":"Park W, Cho S, Ji J, Lewandowski RJ, Larson AC, Kim D-H. Development and validation of sorafenib-eluting microspheres to enhance therapeutic efficacy of transcatheter arterial chemoembolization in a rat model of hepatocellular carcinoma. Radiol: Imaging Cancer. 2021;3(1):e200006.","journal-title":"Radiol: Imaging Cancer"},{"issue":"1","key":"3242_CR25","doi-asserted-by":"publisher","first-page":"29653","DOI":"10.1038\/srep29653","volume":"6","author":"D-H Kim","year":"2016","unstructured":"Kim D-H, Li W, Chen J, Zhang Z, Green RM, Huang S, Larson AC. Multimodal imaging of nanocomposite microspheres for transcatheter intra-arterial drug delivery to liver tumors. Sci Rep. 2016;6(1):29653.","journal-title":"Sci Rep"},{"issue":"20","key":"3242_CR26","doi-asserted-by":"publisher","first-page":"12711","DOI":"10.1021\/acsami.6b03505","volume":"8","author":"W Park","year":"2016","unstructured":"Park W, Chen J, Cho S, Park S-J, Larson AC, Na K, Kim D-H. Acidic pH-triggered drug-eluting nanocomposites for magnetic resonance imaging-monitored intra-arterial drug delivery to hepatocellular carcinoma. ACS Appl Mater Interfaces. 2016;8(20):12711\u20139.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3242_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.biomaterials.2015.05.010","volume":"61","author":"J Chen","year":"2015","unstructured":"Chen J, White SB, Harris KR, Li W, Yap JW, Kim D-H, Lewandowski RJ, Shea LD, Larson AC. Poly (lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. Biomaterials. 2015;61:299\u2013306.","journal-title":"Biomaterials"},{"key":"3242_CR28","doi-asserted-by":"crossref","unstructured":"Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, Real-life Practice Experts for, H. C. C. S. G., Group, H. C. C. Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma. Oncology 2019;97(5), 277\u201385.","DOI":"10.1159\/000501281"},{"issue":"1","key":"3242_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrd.2018.146","volume":"18","author":"J Dawkins","year":"2019","unstructured":"Dawkins J, Webster RM. The hepatocellular carcinoma market. Nat Rev Drug Discov. 2019;18(1):13\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3242_CR30","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jhep.2019.01.028","volume":"70","author":"JM Llovet","year":"2019","unstructured":"Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J Hepatol. 2019;70(6):1262\u201377.","journal-title":"J Hepatol"},{"issue":"1","key":"3242_CR31","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.2021200006","volume":"3","author":"W Park","year":"2021","unstructured":"Park W, Cho S, Ji J, Lewandowski RJ, Larson AC, Kim DH. Development and validation of sorafenib-eluting microspheres to enhance therapeutic efficacy of transcatheter arterial chemoembolization in a rat model of hepatocellular carcinoma. Radiol Imaging Cancer. 2021;3(1): e200006.","journal-title":"Radiol Imaging Cancer"},{"key":"3242_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2014.04.008","volume":"184","author":"J Chen","year":"2014","unstructured":"Chen J, Sheu AY, Li W, Zhang Z, Kim DH, Lewandowski RJ, Omary RA, Shea LD, Larson AC. Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors. J Control Release. 2014;184:10\u20137.","journal-title":"J Control Release"},{"key":"3242_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.biomaterials.2015.05.010","volume":"61","author":"J Chen","year":"2015","unstructured":"Chen J, White SB, Harris KR, Li W, Yap JW, Kim DH, Lewandowski RJ, Shea LD, Larson AC. Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. Biomaterials. 2015;61:299\u2013306.","journal-title":"Biomaterials"},{"issue":"2","key":"3242_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/1097-0142(197202)29:2<435::AID-CNCR2820290227>3.0.CO;2-K","volume":"29","author":"NB Ackerman","year":"1972","unstructured":"Ackerman NB. Experimental studies on the circulation dynamics of intrahepatic tumor blood supply. Cancer. 1972;29(2):435\u20139.","journal-title":"Cancer"},{"issue":"5","key":"3242_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7150\/thno.10823","volume":"5","author":"D-H Kim","year":"2015","unstructured":"Kim D-H, Chen J, Omary RA, Larson AC. MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors. Theranostics. 2015;5(5):477\u201388.","journal-title":"Theranostics"},{"issue":"2","key":"3242_CR36","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.actbio.2013.10.018","volume":"10","author":"DH Kim","year":"2014","unstructured":"Kim DH, Choy T, Huang S, Green RM, Omary RA, Larson AC. Microfluidic fabrication of 6-methoxyethylamino numonafide-eluting magnetic microspheres. Acta Biomater. 2014;10(2):742\u201350.","journal-title":"Acta Biomater"},{"issue":"26","key":"3242_CR37","doi-asserted-by":"publisher","first-page":"1901384","DOI":"10.1002\/adfm.201901384","volume":"29","author":"S Cho","year":"2019","unstructured":"Cho S, Min NG, Park W, Kim S-H, Kim D-H. Janus Microcarriers for magnetic field-controlled combination chemotherapy of hepatocellular carcinoma. Adv Func Mater. 2019;29(26):1901384.","journal-title":"Adv Func Mater"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-022-03242-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:26:59Z","timestamp":1669706819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-022-03242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3242"],"URL":"https:\/\/doi.org\/10.1007\/s00270-022-03242-8","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"12 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, consent for publication is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For this type of study, informed consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}